Edwards Lifesciences Net Profit Margin 2010-2022 | EW

Current and historical net profit margin for Edwards Lifesciences (EW) from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Edwards Lifesciences net profit margin for the three months ending March 31, 2022 was .
Edwards Lifesciences Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $5.36B $1.54B 28.73%
2021-12-31 $5.23B $1.50B 28.72%
2021-09-30 $5.10B $1.48B 29.01%
2021-06-30 $4.93B $1.46B 29.70%
2021-03-31 $4.48B $0.85B 19.02%
2020-12-31 $4.39B $0.82B 18.78%
2020-09-30 $4.37B $0.79B 18.17%
2020-06-30 $4.32B $0.74B 17.21%
2020-03-31 $4.48B $1.11B 24.71%
2019-12-31 $4.35B $1.05B 24.08%
2019-09-30 $4.15B $0.77B 18.64%
2019-06-30 $3.97B $0.73B 18.28%
2019-03-31 $3.82B $0.77B 20.04%
2018-12-31 $3.72B $0.72B 19.41%
2018-09-30 $3.64B $0.71B 19.61%
2018-06-30 $3.55B $0.66B 18.51%
2018-03-31 $3.45B $0.56B 16.24%
2017-12-31 $3.44B $0.58B 16.96%
2017-09-30 $3.32B $0.75B 22.47%
2017-06-30 $3.23B $0.72B 22.15%
2017-03-31 $3.15B $0.66B 20.86%
2016-12-31 $2.96B $0.57B 19.24%
2016-09-30 $2.87B $0.55B 19.26%
2016-06-30 $2.74B $0.53B 19.29%
2016-03-31 $2.60B $0.52B 19.80%
2015-12-31 $2.49B $0.50B 19.85%
2015-09-30 $2.44B $0.46B 18.97%
2015-06-30 $2.43B $0.44B 18.09%
2015-03-31 $2.39B $0.87B 36.57%
2014-12-31 $2.32B $0.81B 34.93%
2014-09-30 $2.24B $0.78B 34.69%
2014-06-30 $2.13B $0.76B 35.65%
2014-03-31 $2.07B $0.31B 14.73%
2013-12-31 $2.05B $0.39B 19.01%
2013-09-30 $2.02B $0.40B 19.95%
2013-06-30 $1.97B $0.40B 20.03%
2013-03-31 $1.94B $0.37B 19.10%
2012-12-31 $1.90B $0.29B 15.32%
2012-09-30 $1.82B $0.27B 14.57%
2012-06-30 $1.78B $0.25B 13.90%
2012-03-31 $1.73B $0.24B 13.73%
2011-12-31 $1.68B $0.24B 14.12%
2011-09-30 $1.64B $0.24B 14.56%
2011-06-30 $1.58B $0.24B 14.90%
2011-03-31 $1.51B $0.24B 15.55%
2010-12-31 $1.45B $0.22B 15.13%
2010-09-30 $1.40B $0.20B 14.41%
2010-06-30 $1.38B $0.23B 16.53%
2010-03-31 $1.35B $0.22B 16.15%
2009-12-31 $1.32B $0.23B 17.46%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $59.122B $5.233B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $212.673B 21.60
Alcon (ALC) Switzerland $34.252B 29.87
STERIS (STE) Ireland $20.632B 26.06
Fresenius Medical Care AG KGaA (FMS) Germany $14.616B 13.13
Teleflex (TFX) United States $11.530B 18.43
Globus Medical (GMED) United States $5.712B 28.50
Penumbra (PEN) United States $4.692B 296.48
Integer Holdings (ITGR) United States $2.339B 18.17
Glaukos (GKOS) United States $2.150B 0.00
Nevro (NVRO) United States $1.545B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.294B 23.17
Paragon 28 (FNA) United States $1.213B 0.00
Artivion (AORT) United States $0.759B 82.09